Predicted to enable scaffold protein binding activity and scavenger receptor activity. Predicted to act upstream of or within acute-phase response. Predicted to be located in cell surface and plasma membrane. Predicted to be active in external side of plasma membrane. Is expressed in several structures, including gut; immune system; male reproductive gland or organ; olfactory lobe; and quadriceps femoris muscle. Orthologous to human CD163 (CD163 molecule).
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of CD163 mRNA, [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CD163 mRNA
bardoxolone methyl inhibits the reaction [Lipopolysaccharides results in increased expression of CD163 mRNA], bardoxolone methyl inhibits the reaction [Lipopolysaccharides results in increased expression of CD163 protein]
[bisphenol A co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-benzyl phthalate co-treated with monobutyl phthalate] results in decreased expression of CD163 mRNA, [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of CD163 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CD163 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of CD163 mRNA, [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CD163 mRNA
[Carbon Tetrachloride co-treated with Ethanol] results in decreased expression of CD163 mRNA, [Fructose co-treated with Ethanol] results in increased expression of CD163 mRNA
[gadolinium chloride co-treated with Fructose co-treated with Copper deficiency] results in decreased expression of CD163 mRNA, gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of CD163 mRNA]
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of CD163 mRNA, [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CD163 mRNA
bardoxolone methyl inhibits the reaction [Lipopolysaccharides results in increased expression of CD163 mRNA], bardoxolone methyl inhibits the reaction [Lipopolysaccharides results in increased expression of CD163 protein]
[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of CD163 mRNA, gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of CD163 mRNA]
[bisphenol A co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-benzyl phthalate co-treated with monobutyl phthalate] results in decreased expression of CD163 mRNA
[bisphenol A co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-benzyl phthalate co-treated with monobutyl phthalate] results in decreased expression of CD163 mRNA
[bisphenol A co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-benzyl phthalate co-treated with monobutyl phthalate] results in decreased expression of CD163 mRNA
[Diethylnitrosamine co-treated with Phenobarbital] results in decreased expression of CD163 mRNA, NR1I3 protein affects the reaction [Phenobarbital results in decreased expression of CD163 mRNA]
[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of CD163 mRNA, gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of CD163 mRNA]
[bisphenol A co-treated with Testosterone] results in decreased expression of CD163L1 mRNA, [estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CD163 mRNA
Monocyte expression and soluble levels of the haemoglobin receptor (CD163/sCD163) and the mannose receptor (MR/sMR) in septic and critically ill non-septic ICU patients.
Expression of CD206 and CD163 on intermediate CD14++CD16+ monocytes are increased in hemorrhagic fever with renal syndrome and are correlated with disease severity.